Autres langues Allergan plc

Actions

AGN

IE00BY9D5467

Produits pharmaceutiques

Temps Différé Nyse Autres places de cotation			Varia. 5j.	Varia. 1 janv.
- ^USD	-.--%		+1,73 %	+0,97 %

12/02	Allergan Aesthetics lance trois nouveaux centres de formation aux États-Unis pour élargir l'accès à une formation esthétique de haute qualité	CI
2024	BOTOX® Cosmétique (onabotulinumtoxinA) reçoit l'approbation de la FDA pour les bandes verticales modérées à sévères reliant la mâchoire et le cou (bandes platysma)	CI

Autres langues

Allergan Aesthetics to Launch Three New Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training	12/02
BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)	19/10/24
Allergan Aesthetics Announces the Launch of Its Next Generation Hydration Product: Skinmedica HA5 Hydra Collagen Replenish + Restore Hydrator	27/08/24
Allergan Aesthetics Debuts Alle Payment Plans	27/06/24
Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	01/04/24
Allergan Aesthetics Announces the U.S. FDA Approval of JUVEDERM VOLUMA XC for Injection in the Temple Region to Improve Moderate to Severe Temple Hollowing in Adults over the Age of 21	05/03/24
Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of Onabotulinumtoxina for the Treatment of Platysma Prominence	18/09/23
Allergan Aesthetics Announces the Journal of Cosmetic Dermatology Publishes Data Demonstrating Patient Satisfaction with Natural-Looking Outcomes Following Treatment with OnabotulinumtoxinA (BotoX®? Cosmetic)	30/08/23
Allergan plc Announces U.S. FDA Approval of SKINVIVE™ by JUVÉDERM®	15/05/23
Allergan Aesthetics Announces the Highly Anticipated National Launch of Juvéderm® Volux™ Xc	18/01/23
Allergan Aesthetics Announces the Launch of the Long-Awaited SkinMedica Even & Correct Collection	17/01/23
Allergan Aesthetics to Present Data from Its Leading Aesthetic Portfolio At the 2022 American Society for Dermatologic Surgery Meeting	07/10/22
Allergan Aesthetics Announces the Launch of SkinMedica Firm & Tone Lotion for Body	31/08/22
FDA Approves JUVÉDERM® VOLUX™ XC for Improvement of Jawline Definition	03/08/22
Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics	13/06/22
Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	20/04/22
Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	06/04/22
PatientFi Expands Partnership with Allergan Aesthetics	06/04/22
AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	22/03/22
Allergan plc completed the acquisition of Soliton, Inc. for approximately $570 million.	16/12/21
Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	10/12/21
Allergan Aesthetics to Present Data from its Aesthetic Portfolio at the 2021 American Society for Dermatologic Surgery Virtual Meeting	19/11/21
Allergan, an AbbVie Company, to Present New Data on Investigational AGN-190584 for the Treatment of Presbyopia	27/10/21
Allergan, an AbbVie Company, to Present New Data on Investigational AGN-190584 for the Treatment of Presbyopia	26/10/21
Hagens Berman: Law Firm Investigating Permanent Injuries and Disfigurement from Botched CoolSculpting Procedures	05/10/21

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Allergan plc

Actions

AGN

IE00BY9D5467

Produits pharmaceutiques

Autres langues

Filtres